

AMENDMENTS TO THE CLAIMS

Claims 33-47 are pending in the application.

Claims 33, 36 and 37 are being amended. Claim 34 is being canceled. After the amendments, claims 33 and 35-47 will be pending.

This listing of claims replaces all prior versions and listings of claims in the application:


Listing of Claims:

1.-32. (Canceled)

33. (Currently amended) A method for the treatment of a disease selected from the group consisting of transplantation rejection, host v. graft disease, graft v. host disease, leukemia/lymphoma, hyperproliferative vascular disorder, ~~autoimmune disease~~ multiple sclerosis, rheumatoid arthritis, inflammatory disease, ~~solid tumors~~, and fungal infection, comprising administering to an animal in need thereof an effective amount of a glycosylated deuterorapamycin or a pharmaceutically acceptable salt thereof, wherein the glycosylated deuterorapamycin is glycosylated at position 42 of a deuterorapamycin selected from the group consisting of 7-deuteromethyl rapamycin, epi-7-deuteromethyl rapamycin, 31d-rapamycin, 7,43-d<sub>6</sub>-rapamycin, 31,42-d<sub>2</sub>-rapamycin, and isomers thereof.

34. (Canceled)

35. (Previously presented) The method of claim 33 wherein the glycosylated deuterorapamycin has the structure:



36. (Currently amended) The method of claim 33 wherein the disease is selected from the group consisting of transplantation rejection, host v. graft disease, graft v. host disease, ~~autoimmune disease~~ multiple sclerosis, rheumatoid arthritis, and inflammatory disease.

37. (Currently amended) The method of claim 33 wherein the disease is selected from the group consisting of leukemia/lymphoma[, ] and hyperproliferative vascular disorder, ~~and solid tumors~~.

38. (Previously presented) The method of claim 33 wherein the disease is a fungal infection.

39. (Previously presented) The method of claim 33 wherein the animal in need is a human.

40. (Previously presented) The method of claim 33 wherein the glycosylated deuterorapamycin or pharmaceutically acceptable salt thereof is administered as a pharmaceutical composition comprising the glycosylated deuterorapamycin or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
41. (Previously presented) The method of claim 40 wherein the pharmaceutically acceptable carrier is selected from the group consisting essentially of a solid carrier and a liquid carrier.
42. (Previously presented) The method of claim 40 wherein the pharmaceutically acceptable carrier is a solid carrier.
43. (Previously presented) The method of claim 40 wherein the pharmaceutically acceptable carrier is a liquid carrier.
44. (Previously presented) The method of claim 40 wherein the pharmaceutical composition is in unit dosage form.
45. (Previously presented) The method of claim 40 wherein the pharmaceutical composition is in tablet form.
46. (Previously presented) The method of claim 38 wherein the glycosylated deuterorapamycin or pharmaceutically acceptable salt thereof is administered as a pharmaceutical composition wherein the glycosylated deuterorapamycin or pharmaceutically acceptable salt thereof is a formulation selected from the group consisting of a solution, a cream, and a lotion.
47. (Previously presented) The method of claim 33 wherein the glycosylated deuterorapamycin or pharmaceutically acceptable salt thereof is administered intramuscularly, intraperitoneally, subcutaneously, intravenously, orally, or topically.